Enforcement record
Business Suspension Order disclosure naming 株式会社エール薬品
This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.
Action type
Business Suspension Order
Law
Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices
Authority
Ministry of Health, Labour and Welfare
Action date
13 April 2017
Current page: Enforcement record
This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.
Source verification
Public-source and preservation status
- Publishing authority
- Ministry of Health, Labour and Welfare
- Official source URL
- Recorded by RegBase
- Entity match
- Not confirmed; shown under the published name
- Kiroku preservation
- Queued for preservation
- Captured: Jul 12, 2026, 03:25 PM JST
“Confirmed” means that RegBase matched this record to the cited public disclosure or entity under the stated checks. It does not verify the truth of the disclosure or guarantee the entity’s current status, creditworthiness, or any legal conclusion.
Available sources and saved files are listed in the public documents section below.
Public documents and saved materials
View the original publications, see what was preserved, or download each file below.
Loading materials…
Action summary
- Company
- 株式会社エール薬品Japanese onlyOriginal: 株式会社エール薬品
- Governing law
- Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices医薬品医療機器等法
- Action type
- Business Suspension Order業務停止命令
- Action date
- 13 April 2017
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
- Industry context
- 医薬品卸売業
Violation
Sale of counterfeit products (including distribution).
Show original Japanese text
偽造品の販売（授与を含む。）
Compliance context
HighA formal order requiring suspension of business activities for the covered scope or period.
Japanese regulatory disclosure under Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices.
Escalate for legal or third-party risk review before onboarding or continuing a material relationship.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.